243 related articles for article (PubMed ID: 9688051)
1. Radioligand-binding assay employing P-glycoprotein-overexpressing cells: testing drug affinities to the secretory intestinal multidrug transporter.
Döppenschmitt S; Spahn-Langguth H; Regårdh CG; Langguth P
Pharm Res; 1998 Jul; 15(7):1001-6. PubMed ID: 9688051
[TBL] [Abstract][Full Text] [Related]
2. Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay.
Döppenschmitt S; Langguth P; Regårdh CG; Andersson TB; Hilgendorf C; Spahn-Langguth H
J Pharmacol Exp Ther; 1999 Jan; 288(1):348-57. PubMed ID: 9862789
[TBL] [Abstract][Full Text] [Related]
3. Affinities at the verapamil binding site of MDR1-encoded P-glycoprotein: drugs and analogs, stereoisomers and metabolites.
Neuhoff S; Langguth P; Dressler C; Andersson TB; Regårdh CG; Spahn-Langguth H
Int J Clin Pharmacol Ther; 2000 Apr; 38(4):168-79. PubMed ID: 10783826
[TBL] [Abstract][Full Text] [Related]
4. Drug binding to P-glycoprotein is inhibited in normal tissues following SDZ-PSC 833 treatment.
Jetté L; Murphy GF; Béliveau R
Int J Cancer; 1998 May; 76(5):729-37. PubMed ID: 9610733
[TBL] [Abstract][Full Text] [Related]
5. Contribution of P-glycoprotein to bunitrolol efflux across blood-brain barrier.
Matsuzaki J; Yamamoto C; Miyama T; Takanaga H; Matsuo H; Ishizuka H; Kawahara Y; Kuwano M; Naito M; Tsuruo T; Sawada Y
Biopharm Drug Dispos; 1999 Mar; 20(2):85-90. PubMed ID: 10206323
[TBL] [Abstract][Full Text] [Related]
6. Pretreatment with potent P-glycoprotein ligands may increase intestinal secretion in rats.
Hanafy A; Langguth P; Spahn-Langguth H
Eur J Pharm Sci; 2001 Feb; 12(4):405-15. PubMed ID: 11231107
[TBL] [Abstract][Full Text] [Related]
7. A functional assay for quantitation of the apparent affinities of ligands of P-glycoprotein in Caco-2 cells.
Gao J; Murase O; Schowen RL; Aubé J; Borchardt RT
Pharm Res; 2001 Feb; 18(2):171-6. PubMed ID: 11405287
[TBL] [Abstract][Full Text] [Related]
8. Multidrug resistance transporter P-glycoprotein has distinct but interacting binding sites for cytotoxic drugs and reversing agents.
Pascaud C; Garrigos M; Orlowski S
Biochem J; 1998 Jul; 333 ( Pt 2)(Pt 2):351-8. PubMed ID: 9657975
[TBL] [Abstract][Full Text] [Related]
9. What kinds of substrates show P-glycoprotein-dependent intestinal absorption? Comparison of verapamil with vinblastine.
Ogihara T; Kamiya M; Ozawa M; Fujita T; Yamamoto A; Yamashita S; Ohnishi S; Isomura Y
Drug Metab Pharmacokinet; 2006 Jun; 21(3):238-44. PubMed ID: 16858128
[TBL] [Abstract][Full Text] [Related]
10. Induction of human P-glycoprotein in Caco-2 cells: development of a highly sensitive assay system for P-glycoprotein-mediated drug transport.
Shirasaka Y; Kawasaki M; Sakane T; Omatsu H; Moriya Y; Nakamura T; Sakaeda T; Okumura K; Langguth P; Yamashita S
Drug Metab Pharmacokinet; 2006 Oct; 21(5):414-23. PubMed ID: 17072095
[TBL] [Abstract][Full Text] [Related]
11. A human lymphocyte based ex vivo assay to study the effect of drugs on P-glycoprotein (P-gp) function.
Parasrampuria DA; Lantz MV; Benet LZ
Pharm Res; 2001 Jan; 18(1):39-44. PubMed ID: 11336351
[TBL] [Abstract][Full Text] [Related]
12. Role of P-glycoprotein-mediated secretion in absorptive drug permeability: An approach using passive membrane permeability and affinity to P-glycoprotein.
Döppenschmitt S; Spahn-Langguth H; Regårdh CG; Langguth P
J Pharm Sci; 1999 Oct; 88(10):1067-72. PubMed ID: 10514357
[TBL] [Abstract][Full Text] [Related]
13. Pharmacophore model of drugs involved in P-glycoprotein multidrug resistance: explanation of structural variety (hypothesis).
Pajeva IK; Wiese M
J Med Chem; 2002 Dec; 45(26):5671-86. PubMed ID: 12477351
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells.
Takanaga H; Ohnishi A; Matsuo H; Sawada Y
Biol Pharm Bull; 1998 Oct; 21(10):1062-6. PubMed ID: 9821810
[TBL] [Abstract][Full Text] [Related]
15. Region-dependent disappearance of vinblastine in rat small intestine and characterization of its P-glycoprotein-mediated efflux system.
Nakayama A; Saitoh H; Oda M; Takada M; Aungst BJ
Eur J Pharm Sci; 2000 Oct; 11(4):317-24. PubMed ID: 11033075
[TBL] [Abstract][Full Text] [Related]
16. Comparison of staurosporine and four analogues: their effects on growth, rhodamine 123 retention and binding to P-glycoprotein in multidrug-resistant MCF-7/Adr cells.
Budworth J; Davies R; Malkhandi J; Gant TW; Ferry DR; Gescher A
Br J Cancer; 1996 May; 73(9):1063-8. PubMed ID: 8624264
[TBL] [Abstract][Full Text] [Related]
17. Characterization of a novel bisacridone and comparison with PSC 833 as a potent and poorly reversible modulator of P-glycoprotein.
Horton JK; Thimmaiah KN; Altenberg GA; Castro AF; Germain GS; Gowda GK; Houghton PJ
Mol Pharmacol; 1997 Dec; 52(6):948-57. PubMed ID: 9415704
[TBL] [Abstract][Full Text] [Related]
18. Expression and function of P-glycoprotein and absence of multidrug resistance-related protein in rat and beige mouse peritoneal mast cells.
Candussio L; Crivellato E; Rosati AM; Klugmann FB; Granzotto M; Giraldi T; Decorti G
Histochem J; 2001 May; 33(5):259-66. PubMed ID: 11563538
[TBL] [Abstract][Full Text] [Related]
19. P-glycoprotein is more efficient at limiting uptake than inducing efflux of colchicine and vinblastine in HL-60 cells.
Declèves X; Chappey O; Boval B; Niel E; Scherrmann JM
Pharm Res; 1998 May; 15(5):712-8. PubMed ID: 9619779
[TBL] [Abstract][Full Text] [Related]
20. The vinblastine binding site adopts high- and low-affinity conformations during a transport cycle of P-glycoprotein.
Martin C; Higgins CF; Callaghan R
Biochemistry; 2001 Dec; 40(51):15733-42. PubMed ID: 11747450
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
